ATM and colorectal carcinoma: Somatic ATM mutations are identified in about 20% of CRC patients, usually occurring in the functional domain as heterozygous variants, and loss of ATM expression is also linked to advanced TNM stage and poor 5-year overall survival (OS) in CRC patients [64,65].